Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the emergence of Roche / Chugai’s bispecific antibody Hemlibra and a diverse pipeline both in terms of technology type and administration route, we forecast a significant change in the approach to disease management of many patients. The emphasis in R&D has shifted away from factor-VIII-replacement-based approaches to new mechanisms aimed at restoring coagulation, including gene therapies. These new therapies include Sanofi’s fitusiran and BIVV001, Novo Nordisk’s concizumab, Pfizer’s marstacimab, and BioMarin’s Roctavian. Despite the various novel nonfactor hemophilia agents forecast to launch, we expect the demand for factor-based concentrates to persist.
How has Hemlibra changed the treatment landscape for hemophilia A for patients with or without inhibitors?
How will hematologists differentiate between the various emerging therapies?
What clinical roles will BIVV001, fitusiran, concizumab, marstacimab, mim8, and gene therapy play in the evolving hemophilia A treatment landscape?
How will the management of patients with or without inhibitors change when new treatment options become available?
How will the factor VIII concentrate market evolve? How will nonfactor treatment options affect the multitude of brands vying for patient share in this space?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 25 country-specific interviews with thought-leading hematologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of hemophilia A +/- inhibitors by country; population segmentation by disease severity and inhibitor titer.
Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
Market forecast features: 10-year, annualized, drug-level sales and patient share of key hemophilia A (and inhibitor) therapies through 2031, segmented by brands and epidemiological subpopulations.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.